Whether cellular apoptosis is a primary mechanism promoting steatohepatitis or is a secondary phenomenon resulting from tissue inflammation is under investigation, but the evidence that PGC-1β seems to avoid cell death in steatotic

liver suggests an important role of this coactivator in cellular survival during the development of NASH, thus avoiding the causal relationship between apoptosis and fibrosis that could lead to the progression of steatohepatitis to more severe liver diseases, such as cirrhosis and hepatocarcinoma. Taken together, our findings suggest PGC-1β coactivator as a potential player in the hepatocyte protection against steatohepatitis. Indeed, the ability of PGC-1β mice to induce mitochondrial β-oxidation and promote find more TG clearance in the blood, together with the ability to conserve the Z-VAD-FMK clinical trial expression of metabolic pathways whose transcription is greatly compromised during steatohepatitis, might be the main

mechanisms by which PGC-1β overexpression protects liver from steatohepatitis. In support of the theory that PGC-1β is able to protect from steatohepatitis acting on lipid accumulation through mitochondrial functions and TG clearance, its constitutive activation in mice fed an HFD diet protected also against steatosis. In contrast with previous studies that reported that the PGC-1β dependent up-regulation of mitochondrial proteins is not sufficient to prevent lipid overload in animals fed with HFD,20 in our models hepatic triglyceride and cholesterol levels are greatly reduced, leading to an improvement of steatotic phenotype. These discrepancies could be due to the different models used for this study, since our mice with constitutive overexpression of PGC-1β were challenged with a chronic high-fat feeding. 上海皓元 Nevertheless, it could be interesting to better investigate the differences between acute and chronic overexpression of this coactivator with short- and long-term steatogenic diets. In conclusion, this work bolsters the concept that a combined action

of PGC-1β on lipid synthesis and secretion, as well as on mitochondrial β-oxidation and oxidative phosphorylation, could ameliorate liver disease in steatosis and steatohepatitis progression. We thank S.A. Kliewer, J.M. Taylor, and A. Vidal-Puig for their tools and support. Additional Supporting Information may be found in the online version of this article. “
“See article in J. Gastroenterol. Hepatol. 2012; 27: 888–892. Helicobacter pylori (HP) infection affects 70–90% of the population in developing countries and 25–50% in developed countries.1 HP causes chronic gastritis and development of various gastric and extra-gastric diseases, such as peptic ulcer, stomach cancer, MALToma and adult idiopathic thrombocytopenic purpura.2,3 Eradication of HP has been shown to be effective for preventing and treating such diseases. Therefore, world-wide eradication of HP has long been a desired objective.